Navigation Links
Ibrutinib Data Published in The Lancet Oncology Suggest a Positive Effect in Previously Untreated Chronic Lymphocytic Leukemia Patients Over Age 65
Date:12/9/2013

RARITAN, N.J., Dec. 9, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced data from a study published in The Lancet Oncology, evaluating the safety and activity of ibrutinib as a single-agent therapy in patients over the age of 65 with previously untreated chronic lymphocytic leukemia (CLL, N=29) or small lymphocytic lymphoma (SLL, N=2). The study met its primary endpoint of safety, with data demonstrating treatment with ibrutinib as an initial therapy was associated with adverse events (AEs) that were predominantly Grade 1 or 2 in nature.

Efficacy data were also collected and showed that 71 percent (95% CI, 52.0-85.8) of patients treated with ibrutinib achieved an objective response (defined as a complete or partial response). Although estimates of progression-free survival (PFS) and overall survival (OS) were not reached at the median follow up of 22.1 months, it is estimated that more than 95% of patients would be alive and progression-free at two years.

"This early stage study in previously untreated patients suggests a positive effect with ibrutinib in CLL and SLL," said lead author Susan O'Brien, M.D., Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center. "The results of this study are encouraging given the average age, overall health and unmet needs of the typical CLL population."

Primary Endpoint: Safety

Adverse events were predominantly Grade 1 or 2 in severity, with the most frequently (greater than or equal to 25 percent) reported being diarrhea (68 percent) which was often self-limited and resolved without discontinuation of treatment. Other common mild to moderate AEs that were reported included nausea (48 percent), fatigue (32 percent), hypertension (29 percent), peripheral edema (29 percent), dizziness (26 percent), dyspepsia (26 percent) and upper resp
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. The Leukemia & Lymphoma Society Applauds FDAs Approval of Ibrutinib for Certain Patients with Mantle Cell Lymphoma
2. New Drug Application Filing for Ibrutinib Accepted in Two B-cell Malignancies by the U.S. FDA
3. Study of Mechanism of Action of Ibrutinib in Mantle Cell Lymphoma Published in Blood - Journal of the American Society of Hematology
4. New Drug Application for Ibrutinib Submitted to the U.S. FDA
5. Ibrutinib Monotherapy Clinical Trial Data in Patients with Waldenstroms Macroglobulinemia Presented at the International Conference on Malignant Lymphoma in Lugano, Switzerland
6. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
7. Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
8. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
9. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
10. Ibrutinib Expanded Access Program Open to Eligible U.S. Patients with Relapsed or Refractory Mantle Cell Lymphoma
11. Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , July 3, 2015 ... adquisición del 100% de participación en ZAO "Biocom" ... adquisición marca la incursión de Lupin en el ... de RUB en ventas, colocándolo como uno de ... 2014 (IMS Health). Durante más de una década, ...
(Date:7/2/2015)... SAN DIEGO , July 2, 2015 ResMed ... report its fourth quarter and fiscal year ended June 30, ... York Stock Exchange market close. A press release with ResMed,s ... and the company will host a webcast to discuss operating ... scheduled to begin at 1:30 p.m. US Pacific Time and ...
(Date:7/2/2015)... England , July 2, 2015 ... known as ,Friendly Aedes aegypti , , ... Juazeiro, Brazil by 95%, well ...      (Logo: http://photos.prnewswire.com/prnh/20150630/227348LOGO) , The journal ... a trial of Oxitec,s genetically engineered mosquitoes. The results ...
Breaking Medicine Technology:Lupin adquiere Biocom en Rusia 2Lupin adquiere Biocom en Rusia 3ResMed to Announce Fourth Quarter and Fiscal Year-End 2015 Results 2Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 2Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 3
... Disability Employment Awareness Month marks the 20th ... magazine, the cutting-edge voice of disability culture in America. ... written and edited by staff and freelancers with disabilities, ... society, while simultaneously reflecting the vibrant world of disability-related ...
... (Nasdaq: MASI ), the inventor of Pulse CO-Oximetry(TM) ... , announced today that new clinical studies presented this week ... in New Orleans, Louisiana, show Masimo noninvasive and ... to invasive blood tests for both healthy subjects and hospitalized ...
Cached Medicine Technology:Award-Winning Disability Lifestyle Magazine Celebrates 20 Years of Publication - And 20 Years of Employing People with Disabilities 2New Clinical Studies Demonstrate the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring Technology 2New Clinical Studies Demonstrate the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring Technology 3New Clinical Studies Demonstrate the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring Technology 4New Clinical Studies Demonstrate the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring Technology 5New Clinical Studies Demonstrate the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring Technology 6New Clinical Studies Demonstrate the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring Technology 7
(Date:7/3/2015)... ... July 03, 2015 , ... ... on June 25, 2015 at 1:00pm. The Association welcomed speaker C. Daniel McGillicuddy ... injured bicyclists and practical points of investigating these types of cases. , Each ...
(Date:7/3/2015)... ... July 03, 2015 , ... " Selfie on a Stick ... the latest and coolest technology products available to consumers. Amanda Forstrom, a technology expert ... selfie sticks are great for documenting memories. , Almost every smartphone has an incredibly ...
(Date:7/2/2015)... ... 2015 , ... sweetFrog Enterprises, LLC. is pleased to announce the opening of its newest location ... Star State. The premium frozen yogurt chain was listed as #22 on the Inc. 500 ... the Village at Bachman Lake, is located at:, 3701 W. Northwest Highway, STE 430, Dallas, ...
(Date:7/2/2015)... ... July 02, 2015 , ... Many Fourth of July celebrations will ... Amica Insurance is sharing some tips to promote the proper use of ... go to the emergency room daily with fireworks-related injuries in the month surrounding the ...
(Date:7/2/2015)... GA (PRWEB) , ... July 02, 2015 , ... ... sporting the newest shades of the SIGVARIS PERFORMANCE SOCKS. Since the socks were ... experts and athletic trainers. Their significant popularity has inspired four new, fun shades ...
Breaking Medicine News(10 mins):Health News:Attorney from William Mattar Leads Discussion on Bicycle Accidents 2Health News:Learn How to Take Selfies like Kendall Jenner 2Health News:sweetFrog Opens 18th Location in the Lone Star State 2Health News:6 Fireworks Safety Tips from Amica Insurance 2Health News:SIGVARIS is Sporting Four Brand New Colors in the Popular PERFORMANCE SOCK Product Line 2
... have uncovered some remarkable results on how eastern and ... two studies, participants viewed images, each of which consisted ... each image. The researchers manipulated the facial emotion (happy, ... asked the participants to determine the dominant emotion of ...
... Secretary of Health Dr.,Calvin B. Johnson today met ... to discuss Governor Edward G. Rendell,s plan to,provide ... of uninsured,adults through his "Cover All Pennsylvanians" proposal., ... help prevent disease,successfully manage chronic diseases such as ...
... to meet the needs of emerging low-profile beds and ... ... the newer model beds,and stretchers emerging onto the healthcare market utilize components ... of the,floor. This means traditional mobile patient lifts can be difficult to ...
... relieve pain or boost immune status , , WEDNESDAY, March 5 ... it actually good for you? , Researchers are reporting that ... nothing to heal wounds, relieve pain or enhance immune status, ... some cases, distilled water showed more of a salutary effect, ...
... with special,health care needs have higher than average ... sources of health care when they are ill, ... Administration (HRSA),indicates., The latest edition of the ... Chartbook 2005-2006 ( http://mchb.hrsa.gov/cshcn05/ ),reports that 10.2 million ...
... March 5 The DFW Partnership for Peak ... Dallas-Fort Worth,Business Group on Health (DFWBGH) to improve ... announced today that it has selected a data,aggregator ... of diabetes. Austin Provider Solutions (APS) will manage ...
Cached Medicine News:Health News:When it comes to emotions, Eastern and Western cultures see things very differently: Study 2Health News:Pennsylvania Health Secretary Urges Prompt Action on Health Insurance for All Pennsylvanians 2Health News:Liko Introduces New LowBase(TM) Model of Its Popular Golvo Mobile Lift 2Health News:Aromatherapy Falls Short, Study Finds 2Health News:Aromatherapy Falls Short, Study Finds 3Health News:High Numbers of Children With Special Needs Have Health Insurance, Regular Caregivers, HRSA Survey Finds 2Health News:DFW Partnership for Peak Health Care Performance Selects Data Aggregator for Diabetes Treatment Program 2
... is an easy-to-use, automated system that enables ... assays for managing hemostatic disordersincluding D-Dimer, Von ... offers reflex and rerun testing for greater ... by our high-quality service to help your ...
... Embolic Protection System is designed to provide ... when performing carotid stenting interventions. The ACCUNET ... system that utilizes rapid exchange technology so ... filter during catheter manipulations. It is available ...
Four disposable disc electrodes are pre-gelled and attached to wires in red, blue, black and green. 4mil carbon film, Ag/AgCl coated. Each package contains 20 individually sealed sets of four leads....
Lancet cut ultra sharp tip for low penetration resistance. Low noise and impedance level giving you a clear and reliable signal. Stainless steel needle, color coded attached lead wires. Needles sold ...
Medicine Products: